Neovacs SA (FR:ALNEV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs SA has announced a collaboration with CNRS to develop new lipid formulations for mRNA vaccine delivery, aiming to optimize the efficiency and production speed of mRNA vaccines. The company has invested 100 k€ in the project and will have exclusive rights to the lipids developed for use in human and animal vaccines. This partnership could have significant economic implications for Neovacs due to the current limited availability and high usage costs of existing lipids.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.